CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ 4,664,518	$ (6,864,109)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	32,659	29,539
Stock compensation and warrant expense	1,750,222	308,008
Fair value adjustment on warrant liabilities	(14,702,904)	2,095,220
Net foreign exchange (gain) loss	177	(132,244)
Income from receipt of Mast Therapeutics, Inc. shares	0	(62,945)
Changes in assets and liabilities:
Receivables	85,760	99,508
Interest receivable	(19,311)	(13,651)
Prepaid expenses and other current assets	621,839	(250,057)
Accounts payable	410,109	(1,210,009)
Accrued expenses and other current liabilities	244,378	88,767
Net cash used in operating activities	(6,912,553)	(5,911,973)
Cash flows from investing activities:
(Purchase of)/ Proceeds from sale of short-term investments	(23,500,000)	3,000,000
Purchases of equipment and furnishings	(6,623)	(2,444)
Net cash provided by (used in) investing activities	(23,506,623)	2,997,556
Cash flows from financing activities:
Net proceeds from public offering	80,535,401	0
Proceeds from issuance of restricted stock to employee	100	0
Net proceeds from exercise of warrants	428,891	0
Net cash provided by financing activities	80,964,392	0
Net increase (decrease) in cash and cash equivalents	50,545,216	(2,914,417)
Cash and cash equivalents at beginning of period	11,483,112	14,344,088
Cash and cash equivalents at end of period	62,028,328	11,429,671
Supplemental disclosure of cash flow information:
Equipment and furnishings purchased on credit	7,542	793
Cashless warrant exercises	133	0
Cash paid for income taxes	$ 3,151	$ 1,600